Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Lifted by S&CO Inc.

S&CO Inc. increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,255 shares of the biopharmaceutical company’s stock after acquiring an additional 5,000 shares during the quarter. S&CO Inc.’s holdings in Ultragenyx Pharmaceutical were worth $918,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock worth $116,559,000 after purchasing an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Ultragenyx Pharmaceutical by 81.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock worth $77,815,000 after buying an additional 965,919 shares during the period. Federated Hermes Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 0.3% in the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock worth $74,419,000 after buying an additional 5,400 shares during the period. Deutsche Bank AG grew its holdings in shares of Ultragenyx Pharmaceutical by 0.5% during the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after buying an additional 8,385 shares in the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 3.9% during the first quarter. Alyeska Investment Group L.P. now owns 1,495,351 shares of the biopharmaceutical company’s stock valued at $54,147,000 after buying an additional 55,611 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 10,456 shares of company stock valued at $328,486 over the last three months. Insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $30.63 on Monday. The company has a market capitalization of $2.96 billion, a PE ratio of -5.54 and a beta of 0.30. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $53.04. The business has a 50-day moving average of $31.47 and a 200-day moving average of $32.80.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. During the same period in the previous year, the firm posted ($1.40) EPS. The company’s quarterly revenue was up 14.6% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RARE shares. Wells Fargo & Company assumed coverage on Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They issued an “overweight” rating and a $65.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Wedbush lowered their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Finally, TD Cowen dropped their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $82.75.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.